By Stephen Nakrosis
Acadia Pharmaceuticals on Tuesday said it entered into an exclusive worldwide license agreement with Saniona to develop and commercialize SAN711.
Acadia said it initially plans to develop SAN711 for essential tremor, a neurological condition that includes shaking or trembling in the body. The company said it plans to initiate a Phase 2 study of SAN711 in essential tremor in 2026.
Under the terms of the, Saniona would receive an upfront payment of $28 million, with potential milestone payments of up to $582 million. Saniona is eligible to receive tiered royalties of up to $435 million, Acadia said.
Catherine Owen Adams, Acadia's chief executive officer, said essential tremor is a condition that has not seen innovation in treatment for decades.
Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
November 26, 2024 18:07 ET (23:07 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。